Environmental Monitoring of Aseptic Processing Areas - 1

Similar documents
Aseptic Process Validation

FDA s Guidance for Industry

Overview of a sterility assurance program for PET drugs

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT

Microbiological Consideration for Non-Sterile Pharmaceutical

PhEn-602 Notes # 4 J. Manfredi

Review Validation of aseptic processes for pharmaceuticals

Application of Quality Risk Management Tools for Cell Therapy Manufacturing

MINIMUM REQUIREMENTS FOR A VENDOR

Media Fill A Process Simution. Presented By Shikha Chauhan

Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite

This compilation of the complex

Validation Study on How to Avoid Microbial Contamination during Pharmaceutical Production

Guidance for Industry Sterile Drug Products Produced by Aseptic Processing Current Good Manufacturing Practice

for IND and RDRC Regulated PET Compounding

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Julie Roberts. Audit hot Topics and Regulatory Requirements

UNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL CLEANROOMS

When Quality Matters. Microbial Air Samplers: Selection Criteria in Biopharma Manufacturing. Celebrating Over 50 Years In Business!

ASEPTIC BIOPHARMACEUTICAL MANUFACTURING: FAQs

Current Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)

Aseptic Processing Current Issues & Trends

USP <1116> and Contamination

Fluorescent Sensor Detects Microbes in Real Time

Compounding Aseptic Isolators (CAI) James T Wagner

Process Validation Lifecycle Approach: A Return to Science

Microbiological Cleaning Method Validation

Semiconductor Manufacturing Facility Design

Tests to Support Sterility Claim. Imtiaz Ahmed

Inspection Hot Topics

Quality & Regulatory Issues in Biopharmaceutical Facility Design A Perspective from Industry Trends

ISO Part 1 and Part 2 Compliance Requirements. Cathriona O Neill

USP <797> Compliance Common Challenges and Potential Solutions

Your partner in the pharmaceutical industry

Improving and Optimizing your Viable Environmental Monitoring Program. Jason Willett Midwest Manager Veltek Associates, Inc.

Avoid recurrent microbial contamination using trending of historical data. El Azab Walid Technical Service Manager STERIS

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Study disproves misconception about contamination of sterile IPA bottles.

Update to the Manufacturing Principles for Medicinal Products

Whitepaper. High temperature HEPA filtration. Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Preview

MEASURE FOR MEASURE: QUALITY METRICS

ISO INTERNATIONAL STANDARD. Cleanrooms and associated controlled environments Biocontamination control Part 1: General principles and methods

EU and FDA GMP Regulations: Overview and Comparison

Microbiology Research Associates

Rapid Microbiological Methods Understanding the Technologies and Regulatory Expectations for Validation and Implementation

Chuck Reed at Weiler Engineering, Inc compares aseptic blow-fill-seal technology with traditional aseptic processing of pharmaceutical liquids

Heating, ventilation, and air system encompasses heating, ventilation, and air conditioning, which is integral component of

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

Pharmacy Quality Assurance Commission Sterile Compounding [USP <797>] Self-Assessment Compliance Checklist

Guiding Principles for the implementation of fluid management technologies for modern single use aseptic processing

CGMP for Phase 1 INDs

Questions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility

DISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

Responding to an FDA 483

Study Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.

On-Site GMP Training GMP COMPLIANCE TECHNICAL

Providing clear solutions to microbiological challenges TM. cgmp/iso CLIA. Polyphasic Microbial Identification & DNA Fingerprinting

Requirements of validation of packaging systems and sterility assurance

Advancements on implementation of single use technology in vaccine manufacturing

USP <797> and Environmental Sampling

sterility assurance Prove the power and your processes

FLORIDA SOCIETY OF HEALTH SYSTEM PHARMACISTS NOVEMBER 4, 2016 JAMES T WAGNER CONTROLLED ENVIRONMENT CONSULTING

Managing Aseptic Interventions

Compounding Pharmacies and Water

Managing Your Environmental Isolates

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS

Disinfectant Qualification Bacteria, Fungi, Viruses and Atypical Organisms A Step by Step Workshop

Facility Design for Pharmacy Operation. Full-Scale Nuclear. Slides are not to be reproduced without permission of author.

Draft Guidelines for Radiopharmacy

Utilization of Microbial Data to Improve Food Safety Systems

Validation of Sterilizing Grade Filters

Critical Environment Products and Services

Process Robustness & Challenges to Demonstrating Compliance

STERILIZATION VALIDATION IN THIS SECTION REPROCESSING VALIDATIONS FOR REUSABLE MEDICAL DEVICES. Radiation Sterilization Validation

Test record CFU measurement. Test ID Site/Clinic Spijkenisse

ISO/TC 198. Secretariat: ANSI Sterilization of health care products Microbiological methods

Visible Particles: Regulatory and Compendial Requirements

ISPE Baseline Pharmaceutical Engineering Guide for New and Renovated Facilities Volume 2: Oral Solid Dosage Forms (Revision) Executive Summary

ISO INTERNATIONAL STANDARD

Single-Use Final Fill: Benefits and Considerations

Annex Draft Annex

Inspections, Compliance, Enforcement, and Criminal Investigations

cgmp/iso CLIA Experience Unsurpassed Quality

The validation of biological Active Pharmaceutical

GMP On Site Series. GMP Essentials

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Q&A summary report from PHSS Annual conference 2015; EU GMP Annex 1 revision discussion panel.

ISO INTERNATIONAL STANDARD

Industrial Microorganisms and Product Formation

PDA: A Global. Association. Proposed Revisions to USP <1207> STERILE PRODUCT -

Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology

Reflection paper on the requirements for selection and justification of starting materials for the manufacture of chemical active substances

Available online at ScienceDirect. Procedia Engineering 132 (2015 )

10 Things You Should Do Before You Validate Your Next Package

Transcription:

Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1

Training Course Agenda Overview of Environmental Monitoring Sampling Techniques Action and Alert Limits Environmental Monitoring Laboratory Activities DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 2

Cleanrooms should be monitored for microorganisms and particles Environmental Monitoring Program Requirements: Surface Monitoring Active Air Monitoring Passive Air Monitoring Microbiological Media and Identification Particle Counting Example of a sampling point DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 3

USP 1116 - MICROBIOLOGICAL CONTROL & MONITORING OF ASEPTIC PROCESSING ENVIRONMENTS Recommendations for environments where the risk of microbial contamination is controlled through aseptic processing applied only to clean rooms, RABS, and isolators. EM Program: Documented program implemented via SOPs that describes in detail methods and acceptance criteria for monitoring particulates and microorganisms in controlled environments (air, surface, personnel gear, compressed gases). Includes sampling sites, frequency of sampling, and investigative and corrective actions. ASEPTIC : process for handling sterilized materials in a controlled environment designed to maintain microbial contamination at levels known to present minimal risk. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 4

USP 1116 - MICROBIOLOGICAL CONTROL & MONITORING OF ASEPTIC PROCESSING ENVIRONMENTS ISO 14644 series (Air grade classification with respect to the concentration of total particulates per unit volumen only. No viable particles limits). Consider nonviable particulate contamination in injectable products (see Particulate Matter in Injections 788). In any environment where human operators are present, microbial contamination at some level is inevitable. E.M. results can neither prove nor disprove sterility. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 5

Purpose of an Environmental Monitoring Program: Provides crucial information on the quality of the aseptic processing environment during manufacturing Prevents the release of potentially contaminated batch if appropriate standards are not fulfilled Prevents future contamination by detecting adverse trends DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 6

Why perform EM? Identify events that may cause a room to be dirtier than allowed: Air system failure (e.g.?...) Cleaning was not done properly (e.g.?...) Other factors Processing areas are monitored to catch these problems BEFORE they impact the product. Monitoring = Detection System. Strong limitations: based on limited samples; Microbiological results are not immediate; Bacteria multiplies very fast. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 7

Purpose of EM System To demonstrate that other systems are working Passing EM results through time indicate that other systems are properly supporting the process and that processing is being carried out in a controlled manner: HVAC Facility Cleaning Gowning Facility Other?... Failed EM results indicate that processing is nor being carried out in a controlled manner DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 8

Regulatory FDA: In aseptic processing, one of the most important laboratory controls is the environmental monitoring program. -Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing (Sep. 2004) EU: Clean rooms and clean air devices should be routinely monitored in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean air devices. -Eudralex, Volume 4, Annex 1: Manufacture of Sterile Medicinal Products DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 9

ISO 13408-1 ISO 13408: Aseptic processing of health care products Addresses Environmental Monitoring: EM Program: Should be defined, documented, and maintained with written procedures. Procedures should describe: Frequency of monitoring Type of monitoring Sites monitored Alert and action levels Actions taken when specifications are exceeded DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 10

Elements of EM Program Documentation The EM program should be well-documented. Documents include: Procedures Sampling Plans Risk Assessments Statistical Justification Testing Records Investigation Records Trending Reports Microbiological Validation DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 11

Static or At Rest Monitoring Performed in an area when no processing is occurring EU regulations recommend at least a 15 minute rest period after processing to return the area to a state of rest Used to qualify a new / refurbished facility / maintain the area with no production / prove efficacy of sanitization agents Trending static monitoring results demonstrates that facility systems are in a state of control DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 12

Dynamic Monitoring Monitoring when the process is ongoing. Most important part of EM Monitoring focuses on highest-risk areas Critical operations High traffic areas Grade A spaces Monitoring should not compromise the aseptic process, thus putting the patient at risk. Quiz: Give 2 examples that show how the monitoring activity may compromise the aseptic fill: DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 13

Dynamic Monitoring Results are indicative of the ability of the facility to contain and support the specific process (e.g., Gowning and flows of personnel, equipment, etc.) If static monitoring passes and dynamic fails, the process either needs a better designed cleanroom, equipment technology, or improve cleaning and manufacturing practices Dynamic monitoring limits should be appropriate for the air classification and the specific process Should sterile powder-based processes have a different criteria than liquid processes in the aseptic fill area?. -Address at rest and in-operation conditions DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 14

USP 1116 -ESTABLISHMENT OF SAMPLING PLAN AND MONITORING LOCATIONS Sampling Plan: A documented plan that describes the procedures and methods for sampling a controlled environment; identifies the sampling sites, the sampling frequency, and number of samples; and describes the method of analysis and how to interpret the results. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 15

USP 1116 - -ESTABLISHMENT OF SAMPLING PLAN AND MONITORING LOCATIONS During initial startup or commissioning of a clean room, specific locations for air and surface sampling should be determined. (intensive sampling) Locations considered should include those in proximity of the exposed product, containers, closures, and product contact surfaces of Critical Zone (always ISO 5) WITHOUT creating contamination risk. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 16

USP 1116 - -ESTABLISHMENT OF SAMPLING PLAN AND MONITORING LOCATIONS Microbiological monitoring of environments in which products (and equipment or materials) are filled or processed before terminal sterilization is generally less critical than the monitoring of aseptic processing areas. Classified environments in which closed manufacturing operations are conducted, including fermentation, sterile API processing, and chemical processes, require fewer monitoring sites and less frequent monitoring because the risk of microbial contamination from the surrounding environment is comparatively low. (See WHO Environmental Monitoring of Clean Rooms in Vaccine Manufacturing Facilities: Points to consider for manufacturers of human vaccines, November 2012). DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 17

USP 1116 - -ESTABLISHMENT OF SAMPLING PLAN AND MONITORING LOCATIONS Mapping of the clean room during the qualification phase can provide useful information concerning the movement, positioning of personnel, and the most frequently conducted manipulations and interventions, including entry points where equipment and materials move from areas of lower classification to those of higher classification, within and around doors and airlocks, etc. Sampling of walls and floors based on a grid approach also provides an indication of sanitization effectiveness. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 18

USP 1116 - -ESTABLISHMENT OF SAMPLING PLAN AND MONITORING LOCATIONS Sampling scheme based on: Standard normative (eg, WHO 961) recommendations Prospective risk assessment and a rationale for sampling locations and frequencies (and methods) for each controlled environment. EM History / Trends Qualification / Requalification data Process (eg, duration, complexitiy, number of personnel, technology, closed/open, equipment breakdowns, handling of live organisms) DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 19

Personnel Personnel are monitored regularly to ensure they are not contaminating their gowns If an operator was clean at the end, he or she was likely clean throughout the activity DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 20

Sample Sites FDA Guidance on Aseptically Produced Drugs: The monitoring program should cover all production shifts and include air, floors, walls, and equipment surfaces, including the critical surfaces that come in contact with the product, container, and closures. Air and surface samples should be taken at the locations where significant activity or product exposure occurs during production. It is especially important to monitor the microbiological quality of the critical area to determine whether or not aseptic conditions are maintained during filling and closing activities. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 21

Sample Sites FDA Guidance on Aseptically Produced Drugs: Critical surface sampling should be performed at the conclusion of the aseptic processing operation to avoid direct contact with sterile surfaces during processing. When identifying critical sites to be sampled, consideration should be given to the points of contamination risk in a process, including factors such as difficulty of setup, length of processing time, and impact of interventions. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 22

Continuous total particle Monitoring in class A DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 23

Record of Continuous total particle monitoring in class B DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 24

Total particle monitoring in UDAF Isocinetic sampling: Captures particles at the same speed as the velocity of the surrounding air, avoiding distorsion of the relationships between particles of different sizes. Required in laminar flow areas (90 ft/min. or 0.45 m/sec). Isocinetic probe DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 25

Sample Frequency Dynamic Monitoring is required for all critical operations Total Particles (TP) TP Monitoring may be a series of samples (e.g. for class C or D), or continual monitoring + series of samples (e.g. for class A and B) Filling and other grade A finishing operations MUST be continually monitored for particulates. Microbial Continual monitoring for microbes in class A and B should be performed; Settling plates meet this expectation. Why are settling plates are recommended to monitor class A during operations rather than active air samplers? DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 26

Sample Frequency Eudralex Volume 4, Annex 1 The Grade A zone should be monitored at such a frequency and with suitable sample size that all interventions, transient events and any system deterioration would be captured and alarms triggered if alert limits are exceeded. Risk Assessment Analysis: Analysis of the identification of contamination potentials in controlled environments that establish priorities in terms of severity and frequency (of occurrence) and that will develop methods and procedures that will eliminate, reduce, minimize, or mitigate their potential for microbial contamination of the product/container/closure system. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 27

Sample Frequency DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 28

TIPS for Sampling Decisions Know your facility and process Assess your facility and process for risks and function Develop a plan that is appropriate for your facility and process Document your decisions so you can defend them to regulators DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 29

Air Particulate Monitoring Provides immediate results Serves as a go / no-go decision point Does not differentiate between viable and non-viable particles The scattering of laser light by each particle shows the size and number of particles Annex 1 UE: - Airborne particle monitoring systems Where remote sampling systems are used, the length of tubing and the radio of any bends in the tubing must be considered in the context of particle losses in the tubing. DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 30

Air Particulate Monitoring DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 31

DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 32